Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study

Fig. 1

Primary endpoint: the incidence of grade 2–3 oral mucositis between the Pmab and Cmab groups. The number of patients (N) and the incidence of oral mucositis (%) of each grade are shown in the bar charts. The incidence of oral mucositis was the following (Pmab group vs Cmab group); All grades: 24 (75%) vs 31 (72%), p > 0.05. grade 2–3: 10 (31.3%) vs 4 (9.3%), p < 0.05. grade 3: 6 (18.8%) vs 0 (0%), p < 0.01

Back to article page